Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacokinetic Characteristics of 6-Hydroxykaempferol-3,6-Diglucoside in Normal and Diabetic Cardiomyopathy Mice.

Biomedical chromatography : BMC·2026

Same author

High-Level Production of Ergothioneine in Yarrowia lipolytica via Systematic Metabolic Engineering Strategies.

Biotechnology and bioengineering·2026

Same author

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.

Science advances·2026

Same author

Advances in polyethylene biodegradation and bioconversion: Microbial, enzymatic, and biotechnological insights.

Engineering microbiology·2026

Same author

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

Nature communications·2026

Same author

A comparative analysis of serum and tissue proteomic profiles in non-small cell lung cancer patients with or without brain metastasis.

Cell death discovery·2026

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

RNA interference therapy for glioblastoma.

Dongsheng Guo¹, Baofeng Wang, Fuxin Han

¹Department of Neurosurgery, Huazhong University of Sciences and Technology, Tongji Medical College, Tongji Hospital, Wuhan, China. guodongsheng@yahoo.com

Expert Opinion on Biological Therapy

|April 27, 2010

Summary

RNA interference (RNAi) therapy shows promise for treating glioblastoma, a deadly brain tumor. Combining RNAi with other treatments may improve outcomes, but further research is needed for effective delivery and targeting.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 13, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Oncology
Molecular Biology
Gene Therapy

Background:

Glioblastoma prognosis remains poor despite advances in brain tumor therapy.
Recurrent glioblastoma lacks effective treatment options, necessitating novel therapeutic strategies.
RNA interference (RNAi) offers a powerful gene silencing approach for glioblastoma treatment.

Purpose of the Study:

To review the progress and challenges in RNAi therapy for glioblastoma.
To cover pre-clinical and clinical research from 2003 to 2009.

Main Methods:

Discussion of RNA interference (RNAi) therapy principles.
Categorization of RNAi triggers and delivery systems.
Review of pre-clinical and clinical studies evaluating RNAi for glioblastoma.

Main Results:

RNAi therapy involves specific gene silencing mechanisms.
Various RNAi triggers and delivery systems are under investigation.
Current studies assess RNAi's potential as a glioblastoma therapeutic strategy.

Conclusions:

Combination therapy with RNAi and other agents may benefit glioblastoma patients.
Development of efficient delivery systems and specific gene targets is crucial.
Further research is needed to optimize treatment protocols and clinical response measures.